Kynam Capital Management, LP
PRINCETON, NJ · CIK 1907884 · 13F filing filed 2024-08-14
SEC-registered investment adviser since 2022 · limited partnership
- Assets managed$2.4bn
- Staff3 · 2 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds1 (1 hedge) · $2.4bn gross assets
- Form ADV · 2026-04-10SEC adviser record
- Legal entityKYNAM CAPITAL MANAGEMENT, LP (US)
- Kindhedge funds, futures
- Others nearbyPrinceton, NJ
As an employer
- Private fundshedge 1
$955.2m
reported value
+6.3% vs Q1 2024
22positions
87.6%in top 10
2 new
17 added
2 reduced
1 sold out
vs Q1 2024
Options: 1 call positions ($67.0m notional), 3 put positions ($274.2m notional) – listed below, not included above.
Holdings, Q2 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| NATERA INC NTRA | $218.1m22.84% | Added +14.4k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $125.4m13.13% | Added +489.0k |
| SYNDAX PHARMACEUTICALS INC SNDX | $117.5m12.30% | Added +62.1k |
| DYNAVAX TECHNOLOGIES CORP DVAX | $79.5m8.33% | Added +2.8m |
| COGENT BIOSCIENCES INC COGT | $78.1m8.17% | Added +760.4k |
| VAXCYTE INC PCVX | $56.9m5.95% | Added +8.2k |
| VERA THERAPEUTICS INC VERA | $55.8m5.85% | Added +16.9k |
| BIOCRYST PHARMACEUTICALS INC BCRX | $54.5m5.71% | Added +2.3m |
| PROTAGONIST THERAPEUTICS INC PTGX | $27.7m2.90% | Reduced -344.2k |
| 2SEVENTY BIO INC TSVT | $22.9m2.40% | Unchanged |
| VIRIDIAN THERAPEUTICS INC VRDN | $22.8m2.38% | Added +1.6m |
| WAVE LIFE SCIENCES LTD 96663EUR | $19.8m2.08% | Added +43.4k |
| TRAVERE THERAPEUTICS INC TVTX | $16.6m1.74% | Added +21.7k |
| LIQUIDIA CORPORATION LQDA | $11.0m1.15% | Reduced -1.3m |
| IRONWOOD PHARMACEUTICALS INC IRWD | $10.7m1.12% | Added +16.9k |
| TYRA BIOSCIENCES INC TYRA | $9.1m0.95% | Added +51.5k |
| AMARIN CORP PLC SPONS ADR NEW | $8.4m0.88% | Added +132.9k |
| BURNING ROCK BIOTECH LTD BNR | $6.3m0.66% | New |
| SUTRO BIOPHARMA INC COM | $5.9m0.62% | Added +22.0k |
| ACELYRIN INC COM | $3.7m0.38% | Added +434.9k |
| CARIBOU BIOSCIENCES INC CRBU | $2.7m0.28% | Added +578.2k |
| CG ONCOLOGY INC CGON | $1.7m0.18% | New |
Sold out since Q1 2024
| Security | Value then |
|---|---|
| BURNING ROCK BIOTECH LTD | $7.0m9.6m shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| VERTEX PHARMACEUTICALS INC VRTX · Put | $154.7m330.0k shares | Added |
| SPDR S&P 500 ETF TR SPY · Put | $109.1m200.0k shares | New |
| INSMED INC INSM · Call | $67.0m1.0m shares | New |
| ALNYLAM PHARMACEUTICALS INC ALNY · Put | $10.4m43.0k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| BURNING ROCK BIOTECH LTD 13G · filed 2026-05-15 | 14.0% |
| SYNDAX PHARMACEUTICALS INC SNDX · 13G · filed 2025-02-14 | 10.0%≈ $186.2m |
| CYTOMX THERAPEUTICS INC CTMX · 13G · filed 2026-08-14 | 10.0% |
| CELLDEX THERAPEUTICS INC NEW CLDX · 13G · filed 2026-08-14 | 6.8% |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 5.7% |
| SUTRO BIOPHARMA INC 13G · filed 2026-05-15 | 5.3% |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2026-03-04 | 5.3%≈ $56.7m |